Clinical Trial Update: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates IDP-023 is being studied as a single agent and in combination with antibody therapies in advanced hematologic cancers, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• IDP-023

Snippet

Sponsor: Indapta Therapeutics, INC. | Conditions: NHL, Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING